Mayne Pharma Group Ltd (ASX: MYX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mayne Pharma Group Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$206.36 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
81.25 million
Earnings per share
-1.043
Dividend per share
0.04
Year To Date Return
-20.26%
Earnings Yield
N/A
Franking
100%
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mayne Pharma Group Ltd (ASX: MYX)
Latest News
Healthcare Shares
The ASX stocks that could enjoy a consensus earnings upgrade this reporting season
How to invest
Here's how to start investing with $5k
Share Market News
These 2 ASX medical shares are on the rise after major announcements
Share Gainers
Why Electro Optic Systems, Mayne Pharma, Tyro, & WAM Leaders are racing higher
Share Market News
Mayne Pharma share price on watch after announcing major Novast Laboratories agreement
Healthcare Shares
Why the Mayne Pharma share price is climbing today
Share Market News
These 5 ASX shares saw the biggest losses last week
⏸️ TMF AMP
ASX 200 Weekly Wrap: ASX back in the green
Share Fallers
These were the worst performers on the ASX 200 last week
Share Market News
ASX 200 finishes higher by 0.8%, Carsales share price driven up by FY20 guidance
Share Market News
ASX 200 down 0.1%: Carsales update impresses, a2 Milk surges higher
Share Market News
The ASX winners and losers from the latest S&P index shake-up
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 18 Jan 2023 | $0.0272 | 100.00% | Special Cash | 27 Jan 2023 |
MYX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mayne Pharma Group Ltd
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
MYX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Mar 2026 | $2.54 | $0.06 | 2.42% | 397,068 | $2.50 | $2.55 | $2.44 |
| 05 Mar 2026 | $2.48 | $0.09 | 3.77% | 343,911 | $2.40 | $2.54 | $2.37 |
| 04 Mar 2026 | $2.39 | $-0.01 | -0.42% | 197,160 | $2.37 | $2.43 | $2.35 |
| 03 Mar 2026 | $2.40 | $-0.05 | -2.04% | 488,857 | $2.45 | $2.48 | $2.36 |
| 02 Mar 2026 | $2.45 | $-0.07 | -2.78% | 326,842 | $2.48 | $2.50 | $2.42 |
| 27 Feb 2026 | $2.52 | $-0.01 | -0.40% | 415,102 | $2.58 | $2.58 | $2.48 |
| 26 Feb 2026 | $2.53 | $-0.02 | -0.78% | 205,268 | $2.54 | $2.58 | $2.52 |
| 25 Feb 2026 | $2.55 | $0.01 | 0.39% | 262,106 | $2.53 | $2.60 | $2.53 |
| 24 Feb 2026 | $2.54 | $-0.07 | -2.68% | 355,765 | $2.61 | $2.64 | $2.50 |
| 23 Feb 2026 | $2.61 | $-0.04 | -1.51% | 1,296,768 | $2.64 | $2.66 | $2.60 |
| 20 Feb 2026 | $2.65 | $0.00 | 0.00% | 252,736 | $2.69 | $2.70 | $2.61 |
| 19 Feb 2026 | $2.65 | $0.01 | 0.38% | 233,763 | $2.66 | $2.67 | $2.62 |
| 18 Feb 2026 | $2.64 | $-0.01 | -0.38% | 222,547 | $2.65 | $2.70 | $2.62 |
| 17 Feb 2026 | $2.65 | $-0.06 | -2.21% | 227,821 | $2.72 | $2.72 | $2.62 |
| 16 Feb 2026 | $2.71 | $0.09 | 3.44% | 452,331 | $2.65 | $2.74 | $2.63 |
| 13 Feb 2026 | $2.62 | $-0.05 | -1.87% | 471,517 | $2.65 | $2.68 | $2.61 |
| 12 Feb 2026 | $2.67 | $-0.28 | -9.49% | 566,421 | $2.95 | $2.95 | $2.64 |
| 11 Feb 2026 | $2.95 | $0.11 | 3.87% | 796,524 | $2.92 | $3.04 | $2.85 |
| 10 Feb 2026 | $2.84 | $0.02 | 0.71% | 280,124 | $2.85 | $2.86 | $2.82 |
| 09 Feb 2026 | $2.82 | $0.19 | 7.22% | 431,768 | $2.70 | $2.85 | $2.68 |
| 06 Feb 2026 | $2.63 | $-0.07 | -2.59% | 398,605 | $2.68 | $2.76 | $2.60 |
| 05 Feb 2026 | $2.70 | $-0.03 | -1.10% | 267,622 | $2.73 | $2.75 | $2.69 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 18 Dec 2025 | Shawn O'Brien | Expiry | 72,821 | $220,647 |
As advised by the company. lapsed, 568193 Rights
|
| 18 Dec 2025 | Shawn O'Brien | Sell | 129,736 | $401,341 |
On-market trade.
|
| 18 Dec 2025 | Shawn O'Brien | Exercise | 326,452 | $989,149 |
Conversion of securities. 641014 rights
|
| 18 Dec 2025 | Shawn O'Brien | Buy | 326,452 | $989,149 |
Conversion of securities.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Professor Bruce Gregory Robinson AC | Non-Executive DirectorNon-Executive Chairman | Aug 2014 |
Prof Robinson is a Non-Executive Director of Cochlear Limited and CS Pharmaceuticals Limited. He is formerly a Board Member of the Woolcock Institute, was Chair of the National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Prof Robinson is Chair of the Science, Technology and Medical Committee.
|
| Ms Ann Custin | Non-Executive Director | Mar 2022 |
Ms Custin, a US resident, has almost 40 years of experience in the healthcare sector. Most recently, Ms Custin was Board Director and CFO of Siemens Medical Solutions (now Siemens Healthineers), a medical technology company with EUR20b in revenues. Previously, she was Chief Operating and Financial Officer of Scient'x Group and President and CEO of USA Draeger Medical Systems. Ms Custin is a Non-Executive Director of Establishment Labs Holdings Inc (NASDAQ:ESTA). Ms Custin is Chair of the Risk Committee.
|
| Dr Kathryn(Katie) MacFarlane | Non-Executive Director | Feb 2022 |
Dr MacFarlane, a US resident, has more than 30 years of experience in the pharmaceutical industry. She is currently Founder and Managing Partner of SmartPharma LLC, offering commercial and strategic consulting services to pharmaceutical companies. Previously, she was Chief Commercial Officer at Agile Therapeutics, Vice President Women's Health Care Marketing, Sales and New Product Planning at Warner Chilcott and Senior Director of Marketing at ParkeDavis (now Pfizer). Dr MacFarlane is a member of the of the Science, Technology and Medical Committee.
|
| Mr David Petrie | Non-Executive Director | Sep 2022 |
Mr Petrie is a M&A executive with over 30 years of advisory experience in public and private mergers and acquisitions, capital management and debt and equity raisings. He is currently Principal at Stratford Advisory Group, an independent corporate and financial advisory firm. Previously, he spent 23 years at Merrill Lynch/Bank of America including Managing Director and Head of Investment Banking Melbourne. He has worked on more than 100 transactions across a range of market sectors including healthcare. Mr Petrie is a member of the Risk Committee and the People Committee.
|
| Ms Laura Loftus | Company Secretary | Mar 2020 |
-
|
| Aaron Gray | Chief Financial Officer |
-
|
|
| Laura Loftus | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 19,388,698 | 23.86% |
| J P Morgan Nominees Australia Pty Limited | 7,192,510 | 8.85% |
| Mr Bruce Mathieson And Related Entities | 5,292,066 | 6.51% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,550,421 | 5.60% |
| HSBC Custody Nominees (Australia) Limited | 4,338,405 | 5.34% |
| BNP Paribas Noms Pty Ltd | 3,356,483 | 4.13% |
| BNP Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 2,283,879 | 2.81% |
| Solium Nominees (Aus) Pty Ltd <Unallocated A/C> | 2,045,519 | 2.52% |
| Bnp Paribas Noms Pty Ltd <Global Markets> | 1,499,974 | 1.85% |
| National Nominees Limited | 873,583 | 1.08% |
| Ecapital Nominees Pty Limited <Accumulation A/C> | 871,082 | 1.07% |
| Ivl Group Pty Ltd | 800,000 | 0.98% |
| Narlack Pty Ltd <Piperoglou Pension A/C> | 720,000 | 0.89% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 713,345 | 0.88% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 524,893 | 0.65% |
| R & R Corbett Pty Ltd <R C Corbett Family A/C> | 522,028 | 0.64% |
| Bnp Paribas Nominees Pty Ltd <Cowen And Co Llc> | 500,000 | 0.62% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 406,602 | 0.50% |
| Dr Kenney Wan | 360,020 | 0.44% |
| Akat Investments Pty Limited <Tag Family No2 Strategic A/C> | 330,000 | 0.41% |